Can we prescribe Pulmicort (fluticasone propionate) for a female patient with eosinophilic esophagitis?

Yes, Pulmicort (budesonide) can be prescribed for eosinophilic esophagitis in female patients, though it requires off-label use with a specific swallowing technique rather than inhalation.

Recommended Approach

Topical corticosteroids are first-line pharmacologic therapy for eosinophilic esophagitis, and swallowed Pulmicort is an effective option 1, 2. However, you must understand that Pulmicort is FDA-approved only for asthma 3, so its use in EoE requires:

• Off-label prescribing with appropriate patient counseling
• Swallowing the medication rather than inhaling it (critical distinction)
• Proper formulation selection and dosing

Choosing Between Budesonide and Fluticasone

While both topical steroids work for EoE, consider:

Budesonide advantages:

• Higher first-pass hepatic metabolism (90%), reducing systemic effects
• Orodispersible formulations specifically designed for EoE exist in Europe (Jorveza®) and the US (Eohilia®) 4
• When using Pulmicort off-label, patients swallow the inhaled formulation

Fluticasone (alternative option):

• Also effective for EoE 5, 6, 7
• Multiple studies demonstrate 50-77% histologic remission rates
• May be more cost-effective in some settings 8

Dosing Protocol for Swallowed Pulmicort

For adults and adolescents ≥12 years:

• Start with 1-2 puffs (180-360 mcg) twice daily swallowed, not inhaled
• Continue for 8-12 weeks before assessing response 2
• Instruct patient to not rinse mouth after swallowing (opposite of asthma use)
• Consider mixing with honey or viscous vehicle to increase esophageal contact time

For children 6-11 years:

• 1-2 puffs (110-220 mcg) twice daily swallowed 5

Treatment Algorithm

1. Initial therapy (8-12 weeks):

   • Swallowed topical steroid OR proton pump inhibitor (PPI) twice daily
   • PPIs are an alternative first-line option 2, 9

2. Assess response with endoscopy and biopsy:

   • Target: <15 eosinophils per high-power field
   • Also evaluate symptoms and endoscopic findings

3. If remission achieved:

   • Continue maintenance therapy indefinitely 2
   • Relapse rates are high (45%) after discontinuation 1
   • May attempt dose reduction by 50% in responders 6

4. If inadequate response:

   • Consider switching between budesonide and fluticasone
   • Increase dose if tolerated
   • Add or switch to PPI if not already tried
   • Consider dietary elimination therapy
   • Refer to specialist for biologics (dupilumab) if refractory 9, 4

Critical Safety Considerations

Monitor for:

• Esophageal candidiasis (15-40% incidence) - usually asymptomatic but treat if symptomatic 1, 5
• Growth in children - studies show normal growth curves with topical steroids 5, but monitor height/weight
• Adrenal suppression - rare with topical use but possible with high doses 3
• Hypersensitivity reactions - discontinue if anaphylaxis, rash, or bronchospasm occurs 3

Important caveats:

• Pulmicort contains lactose with trace milk proteins - contraindicated in severe milk protein allergy 3
• Not for acute symptom relief - patients need rescue medications for food impaction
• Patients should not rinse mouth after swallowing (opposite of asthma instructions)

Guideline Support

Both major guidelines strongly recommend topical steroids over systemic steroids for EoE 1, 2. The AGA/JTF 2020 guideline specifically states topical glucocorticosteroids are preferred, with similar effectiveness to systemic steroids but far fewer side effects (40% systemic complications with prednisone vs 15% oral candidiasis with fluticasone) 1. The British guidelines give a strong recommendation with high-grade evidence for topical steroids inducing histological and clinical remission 2.

Why Not Systemic Steroids?

Avoid oral prednisone - while equally effective for histologic response, systemic steroids cause weight gain, cushingoid appearance, and other significant side effects in 40% of patients compared to 15% oral candidiasis with topical therapy 1. The risk-benefit clearly favors topical administration.